Vaccine protection against Staphylococcus aureus pneumonia

Juliane Bubeck Wardenburg, Olaf Schneewind

Research output: Contribution to journalArticlepeer-review

329 Scopus citations

Abstract

Staphylococcus aureus pneumonia causes significant mortality in hospitalized or healthy individuals, and recent increases in morbidity are attributed to the rapid spread of methicillin-resistant S. aureus (MRSA) strains, which are often not susceptible to antibiotic therapy. α-Hemolysin (Hla), a secreted pore-forming toxin, is an essential virulence factor of MRSA in a mouse model of S. aureus pneumonia. We show that the level of Hla expression by independent S. aureus strains directly correlates with their virulence. Active immunization with a mutant form of Hla (Hla H35L), which cannot form pores, generates antigen-specific immunoglobulin G responses and affords protection against staphylococcal pneumonia. Moreover, transfer of Hla-specific antibodies protects naive animals against S. aureus challenge and prevents the injury of human lung epithelial cells during infection. Thus, Hla vaccination or immunotherapy may prevent S. aureus pneumonia in humans. JEM

Original languageEnglish
Pages (from-to)287-294
Number of pages8
JournalJournal of Experimental Medicine
Volume205
Issue number2
DOIs
StatePublished - Feb 18 2008

Fingerprint

Dive into the research topics of 'Vaccine protection against Staphylococcus aureus pneumonia'. Together they form a unique fingerprint.

Cite this